EN
Search
Photo: The Robot Report

Medtronic's Hugo robot gets FDA clearance for general surgery

Medtronic's Hugo, a robotic-assisted surgery system, has received U.S. clearance for general surgery, the company said. The U.S. Food and Drug Administration cleared the modular, cart-based device for operations across the abdomen.

The clearance covers upper abdominal procedures including gallbladder removal, gastric bypass, ventral hernia repair and small bowel resection. It also covers lower abdominal operations for inguinal hernia and appendix removal. Medtronic estimates that these procedures together make up roughly 3.5 million surgeries a year in the United States.

Medtronic said its open and laparoscopic technologies have a track record of over fifty years, giving it a foothold in many of these areas. Rajit Kamal, who leads robotic surgical technologies at the company, told The Robot Report that Medtronic is pleased with its progress and that Hugo is already in many leading U.S. hospitals for urology.

Medtronic received CE marking for general surgery on Hugo in Europe in 2022, and that clinical data supported its U.S. submission. The company also gained FDA approval for urology in December 2025. In September 2025, it reported that a U.S. hernia repair study met its safety and effectiveness endpoints.

Medtronic also holds an investigational device exemption (IDE) that allows a U.S. clinical trial for general surgery. Kamal described the route as “a creative way of approaching this,” saying it gave the company “a broader set of general surgery indications.”

Medtronic said Hugo is on track to pass 50,000 cumulative procedures worldwide by the end of its fiscal year. General surgery is the system's fastest-growing procedure mix outside the U.S., ahead of urology and gynecology, the company said.

Kamal said AI could play a role before, during and after surgery. He gave planning with imaging as an example before an operation, identifying anatomical and critical structures during surgery, and optimizing recovery afterward. Medtronic also received FDA approval for Touch Surgery Aide, a compute platform for the operating room. The software analyzes surgical video using computer vision and artificial intelligence, then gives surgical teams real-time information.

“We clearly see AI playing a very important role. Our intent is to bring AI features onto our Hugo platform and continue being that partner with the surgeons to use AI to provide them insights and continue to make improvements in terms of the patient outcome,”

Rajit Kamal, general manager of robotic surgical technologies at Medtronic

Traditional laparoscopic operations can be physically demanding, because surgeons often stand for extended stretches while handling tools. Robotic systems such as Hugo let surgeons work from a seated console, which may reduce some of that physical strain. Kamal said surgeons get a magnified 3D image with clear depth perception, and that laparoscopic surgeons who switch to robotics “don't want to go back.”

Medtronic has also invested $700 million in Cornerstone Robotics and gained rights to distribute that company's Sentire surgical system in select markets outside the U.S. where it is approved. Medtronic is also running an IDE study of Hugo in gynecology, evaluating safety and effectiveness during radical, modified radical or total hysterectomies.

On broader access, Kamal said cost, training and support are the key factors. The company is focused on all three and is open to working with hospitals on a financial case for adopting the system. “Access is our number one priority,” he said.

Source